Business
Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6Significant benefits demonstrated on burning pain and on pain interference
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":"Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6Significant benefits demonstrated on burning pain and on pain interference with sleepNo evidence of withdrawal symptoms or rebound pain after treatment ended Conference Call and Webcast Today at 5:00pm ET Hosted by Lexicon Management THE WOODLANDS, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit in Washington, D.C. The oral presentation, titled “A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN-1),” was delivered at 3:35pm ET today. “LX9211 achieved the primary objective of this study by reducing patients’ average daily pain,” said Dr. Anand Patel, the Chief Medical Officer at Conquest Research, a principal investigator in the RELIEF-DPN-1 trial, and presenter of the results. “These final data demonstrate additional positive effects of LX9211 on measures that are very meaningful to patients suffering from painful diabetic neuropathy, including burning pain and sleep interference, which have direct impact on patient quality of life.” Today’s presentation of full data from the entire 11-week evaluation period, which included a 5-week placebo run-off period following the initial 6-week treatment period, showed consistent and statistically significant treatment-period benefits in measures of particular importance in painful diabetic neuropathy (also known as diabetic peripheral neuropathic pain) for both dose arms compared to placebo, such as a reductions in burning pain (p","length":2450,"tagName":"div"}]